More session t t with dasatinib. Updated Aurora Kinase results of 24 months found that the rate of the best CONFIRMS CCR and MMR at any time significantly h Ago dasatinib was that ima tinib. BCR ABL transcripts 0.0032% of sales by 17% and 8% of patients in the dasatinib and imatinib group. In addition, 2.3% of patients were imatinib and dasatinib 5.0% of patients progressed to AP / BC. Dasatinib was generally well tolerated. With regard to the safety car diac, only one patient each experienced in the imatinib and dasatinib groups QTcF 500 msec. There was also some concern about the water retention and pleural effusion of Zion with TKI therapy. In the study DASISION, water retention h Was more often with imatinib, the full impact of PE has performed with dasatinib. Third Factors underlying treatment failure with imatinib has proven its effectiveness, although in most patients ITY, treatment time share S r. Among the reasons that may contribute to treatment failure k, Are at high risk prognostic score at diagnosis, the BCR ABL1 mutations, which mix the leuk Clone resistant to treatment, treatment intolerance, adherence to treatment and poor . make 3.1. The risk score prognostic Sokal and Hasford prognostic scoring systems have been developed to ensure the survival of CML patients at diagnosis, the characteristics SECT COLUMNS able to k, With an h Higher risk scores show worse results. Due to differences in the calculation of two risk scores k These two rating systems can not be compared with each other and risk scores k Con can not be converted easily. Fig. Figure 1 shows the distribution of patients in each risk group at the respective points of the reference time of IRIS, and ENESTnd DASISION studies. In general, it seems that the IRIS study one hour Higher proportion of low-risk patients who did or did ENESTnd DASISION. Interestingly enough, go Gardens patients who have progressed on imatinib arm of both studies preferred to groups of medium and high risk, the discussions on the use of IMA tinib on low-risk Bev Lkerung led, as opposed to the use of second-generation ICT disease high risk. But in testing and ENESTnd DASISION showed nilotinib and dasatinib h MMR here in all risk categories compared to imatinib. 3.2. Resistance is resistance to treatment by the reappearance of leukemic Mix cells characterized, despite treatment. A h INDICATIVE cause of suboptimal response by different mechanisms mechanisms that h Most frequent of which is mediated BCR ABL1 mutations. A mutation, which authorized a high resistance to TKI currently T315I. Reuptake transporters such as hOCT1, were involved in the binding of imatinib with an S Acid glycoprotein, the residual concentrations of imatinib subtherapeu tic, other signaling pathways, and epigenetic Ver Change in resistance of cancer cells. Were initial concerns have been ert U That nilotinib and dasatinib likely to induce mutations to imatinib resistance and. In a secondary Ranalyse ENESTnd the study, however, was the occurrence of mutations Similar between nilotinib and imatinib T315I. In addition, twice as many new detectable BCR ABL mutations appeared with imatinib and nilotinib that LAR had better molecular response kinetics with nilotinib compared to imatinib. For patients in the study say that DASISION.